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Introduction
This is an extremely exciting period in the history of cancer
drug discovery and development. The completion of the
Human Genome Project provides the basis for under-
standing the role of all genes in normal biology and also in
disease pathology [1,2]. The initiation of the Cancer
Genome Project and related activities in cancer genomics
will allow us to define the role of all cancer-causing genes
over the next 5 years [3,4].
Elucidation of the biochemical functions and signalling
pathways that are hijacked by cancer genes will then
follow. Cataloguing the molecular pathology and deregu-
lated wiring diagrams of all cancers provides the intellec-
tual and practical framework for the discovery of innovative
mechanism-based cancer drugs that are more effective
and have fewer side effects than the conventional cyto-
toxic agents of the pregenome era [5–7].
Targeting these new designer cancer drugs to the precise
molecular pathology of the individual patients provides the
basis for a future vision of personalised molecular thera-
peutics for the treatment of all malignant diseases includ-
ing breast cancer. Herceptin, Gleevec (Glivec, STI-571)
and Iressa (ZD1839) represent worked examples of drugs
aimed at cancer genome targets (ErbB2, Bcr-Abl and the
epidermal growth factor receptor, respectively) that
demonstrate promising activity in cancer patients [8].
Many more ‘postgenomic’ drugs are in late preclinical and
early clinical development [5–8].
Despite the enormous promise of cancer genomics and
the emerging signs of clinical benefit with the first genera-
tion of designer drugs, developing effective and selective
new cancer drugs remains a long, challenging, risky and
expensive enterprise. Defining a new cancer gene and val-
idating it as a cancer drug target is only the first step
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[5–7]. It has usually taken 10–15 years or more and cost
in excess of US$500 million to bring a new drug to the
market. In addition to the focus on new molecular targets,
a number of new technologies have been introduced over
the past decade that are designed to improve the chances
of discovering innovative and effective drugs, and also to
shorten the discovery cycle to 5–7 years. High-throughput
screening (HTS) is one of these key methodologies,
together with genomics, informatics, recombinant DNA
technology, combinatorial chemistry, structural biology
and cassette dosing pharmacokinetics [5,6]. The present
commentary examines the role of HTS in contemporary
postgenomic cancer drug discovery.
HTS technology
HTS is now an integral part of the mechanism-based,
small-molecule drug discovery process [9,10] (Fig. 1).
Indeed, in the case of many novel targets for which struc-
tural features of the active site are unknown, a screening
component is vital for finding lead compounds. Such lead
compounds provide the chemical starting points for medi-
cinal chemistry programmes that are designed to optimise
the chemical and biological properties, and to thereby
create a drug molecule that can enter clinical trials (Fig. 1).
This optimisation process is based on the use of a target-
customised cascade of increasingly complex but informa-
tive  in vitro and  in vivo assays and models [9]. It is
essential throughout the process to utilise assays which
demonstrate that the desired mechanism of action is
being targeted.
HTS has evolved rapidly over the past decade into a
highly efficient, integrated, robust and information-rich
scientific discipline. The impetus for this has come from
the following factors: the increased number of targets as a
result of a greater understanding of the genetic basis of
disease; the need to identify new lead compounds; the
huge numbers of compounds now available, especially in
corporate collections; and the medical and economic
need to bring forward new drugs.
Using innovative techniques, imaginative assays and auto-
mated instrumentation, it is now possible to screen com-
pounds at rates that were unthinkable a decade ago.
Screening rates of 10,000 compounds per day are readily
achievable, even in relatively small (compared with large
pharmaceutical companies) academic centres and biotech
companies. The era of ultraHTS (generally defined as the
capability to screen >100,000 compounds per day) is
now practically feasible, but the eventual desirability of
doing this is a subject of fierce debate. The argument in
favour of ultraHTS, favoured by large pharmaceutical com-
panies with huge compound collections, says that the like-
lihood of finding attractive drug development leads is
increased. Many smaller organisations, however, including
biotechnology companies and academic groups such as
Figure 1
The central role of high-throughput screening (HTS) in the mechanism-
based drug discovery process. The criteria for target validation are
presented in Box 1 below.
Box 1. A summary of the criteria that are frequently used for validation
and prioritisation of new targets for drug screening programmes
• The frequency of genetic or epigenetic deregulation of the 
molecular target or pathway in human cancer
– a high frequency indicates that the target or pathway is likely 
to be important in driving the disease
• The linkage of the deregulation to clinical outcome
– a linkage strengthens the case for causal involvement
• Evidence in a model system that the target pathway causes or 
contributes to the malignant phenotype
– such a demonstration (e.g. by transfection) shows a direct 
causal role in malignancy
• Demonstration of reversal of the malignant phenotype
– such evidence (e.g. using gene knockout, dominant negative, 
antisense, ribozyme, RNAi, antibody, peptide or drug leads) 
provides greater confidence that modulation of the target by 
the drug will produce an anticancer effect
• Demonstration of the feasibility tractability or ‘drugability’ of the 
target
– for example, enzymes are generally much more drugable than 
are large-domain protein–protein interactions
• The availability of a robust, efficient biological test cascade to 
support the drug discovery programme
– the appropriate series of assays is essential to allow evaluation 
of lead compounds and to select a development candidate for 
preclinical toxicology testing and clinical trial
• The feasibility of establishing, validating and running an affordable 
and robust high-throughput screen
– a screening campaign can only be run if the appropriate assay 
is available
• The potential for a drug design approach based on structural 
biology
– such an approach, based on an X-ray crystallographic or NMR 
structure, can be highly complimentary to a screening strategy
Note: It should be emphasised that not all of these criteria must be met
to embark on a screening programme. Target validation and selection
is a matter of judgement, balancing levels of confidence and risk. If
several of the criteria are met, confidence levels will be higher and the
risk will be reduced.150
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our own, find that less extensive compound collections,
involving tens of thousands of compounds, can be ade-
quate for the purpose. The use of focused chemical
libraries and virtual screening approaches that utilise com-
putational chemistry and ligand docking techniques
[11,12] may allow the number of compounds actually
screened to be reduced and the hit rates to be increased.
Virtual docking of millions of known compounds into the in
silico structures of drug targets requires considerable
computing power. An interesting development has been
reported [13] in which 35 billion molecules were screened
as potential anti-anthrax agents using the screensavers
running off 1.4 million personal computers in more than
200 countries. According to the article, more than 12,000
potential agents have been provided to the US Govern-
ment. A similar approach is proposed to search for new
anticancer agents.
HTS and ultraHTS capability has been achieved through a
remarkable degree of collaboration between scientists
from many backgrounds (pharmaceutical companies and
biotech firms, academic institutions, instrument manufac-
turers, reagent suppliers and information technologists).
The hallmarks of assays used for modern screening are
miniaturisation and automation. Reducing the volume of
the reaction can bring real savings in reagent costs and
also conserves the supply of precious compounds, as well
as increasing screening rates. This has mainly been
achieved through the introduction of high-density
microtitre plates. The use of standard 96-well plates (well
volume, 150–300 µl) has been largely superseded over
the past decade by the development of assays run in
plates with smaller volume wells (e.g. 384 wells with
50–70 µl volume, and 1536 wells with ~10 µl volume).
Assays designed for even higher density formats (e.g.
9600-well plates) and microformatted chips that rely on
microfluidics have been shown to be possible [14].
This miniaturisation brings with it a number of practical chal-
lenges regarding reagent distribution, pipetting of small
volumes and endpoint measurement. These challenges are
gradually being overcome with the advent of sophisticated
imaging equipment and the use of nanolitre dispensing
options. Automation, either in the form of individual auto-
mated workstations or involving systems that rely com-
pletely on fully integrated robotics, has become an essential
part of the screening environment. It has therefore been
important to design new types of assay that are automation
friendly (e.g. those that have eliminated the need for cen-
trifugation, filtration or extensive wash steps). These so-
called ‘mix and measure’ or homogeneous assays rely on
technologies such as scintillation proximity counting, fluo-
rescence polarisation, fluorescence energy transfer or
quenching and chemiluminescence. Such assay formats
have been described in more detail previously [9,10].
It is now possible to develop assays for all but the most
difficult molecular target. Assays for enzymes (e.g.
kinases, transferases, proteases), receptor binding, and
macromolecular and immunological interactions are most
commonly described. However, there has been a notice-
able trend in recent years to use cell-based assays. In con-
trast to cell-free biochemical assays, cell-based assays
result in the discovery of compounds with activity against
a signalling pathway rather than a specific protein in a
pathway. The identification of the precise target (which
could be a previously known or unknown component of
the pathway) requires a purpose-designed deconvolution
strategy [9]. Cell-based screens, by definition, have the
advantage of identifying cell-permeable compounds. The
types of cell-based screens used include reporter gene
assays [15], assays that measure phenotypic changes
using antibodies to specific post-translational modifica-
tions such as phosphorylation and acetylation [16], and
cell viability assays [17].
Isogenic screens have shown recent promise; for example,
allowing the discovery of compounds with selectivity for
tumour cells with mutant Ras [18]. The use of so-called
chemical genetic [19] screens and screens for synthetic
lethality are increasingly common. Profiling the activity of
compounds in relation to molecular target expression in,
for example, the National Cancer Institute’s panel of 60
human tumour cell lines, can provide valuable information
on mechanism of action and selectivity [20].
Whatever type of assay is used for screening, it is essen-
tial that it is able to identify compounds having the
desired activity with a high degree of statistical certainty.
A large and reproducible window, defined in a number of
ways [21], between the measured signal and the assay
background is therefore required. Hit rates vary
(0.01–2%) with each target and with the concentration
at which compounds are screened. To eliminate false-
positives, hits need to be reconfirmed, relative potency
determined, and the selectivity of the compounds with
respect to related and unrelated enzyme activities needs
to be investigated.
Compound collections and chemical follow-up
The purpose of HTS is to discover compounds that are
good starting points for drug discovery. These are referred
to as ‘hits’. Medicinal chemists study the chemical struc-
tures of compounds that have been found to interact with
the target protein and then build hypotheses to design
related structures with improved properties. Each idea is
then tested by the iterative synthesis and testing of novel
compounds in various biological assays (Fig. 1). The early
phase of this process is usually referred to as ‘hit to lead’
and is designed to probe the potential value of the HTS
hit. A ‘lead’ compound is designated when a series of cri-
teria (including potency, selectivity, synthetic access,151
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‘drug-like’ properties [see later] and potential for further
optimisation) are met. Structural changes associated with
improved properties in the lead are then pursued vigor-
ously until a compound is found that meets the stringent
criteria required of a preclinical drug candidate. It is not
uncommon for projects to be abandoned because the
required profile is not attained, despite synthesis and
testing of many hundreds of compounds.
The main focus of effort in the early stages of a project is
to improve potency, then selectivity. Lack of progress due
to a poor lead is evident and, with decisive project man-
agement, the waste of time and resource can be minimal.
However, failure due to inadequate pharmacokinetic prop-
erties and unacceptable toxicity are often encountered at
a much later stage after considerable expenditure.
Lipinski  et al. recently analysed the structural features
associated with successful drugs (i.e. with good pharma-
cokinetic properties) [22]. They then formulated an empiri-
cal ‘Rule of 5’ that can be used to predict whether a
compound would be expected to have drug-like proper-
ties. The basis for the Lipinski Rule of 5 is that most suc-
cessful drugs have the following features: molecular
weight, <500 Da; log P (as a measure of lipophilicity),
<5; number of hydrogen bond donors, <5; number of
oxygen plus nitrogen atoms, <10.
Some physicochemical properties relating to the Lipinski
Rule of 5 are presented in Fig. 2 for several molecularly
targeted compounds that have progressed to the clinic.
Using this simple Rule of 5 method, supported by experi-
mental characterisation (especially for evaluation of
metabolic stability), hits from HTS may be assessed
before committing significant resource for chemical opti-
misation. There is no reliable method for predicting toxic-
ity as a function of chemical structure, but compounds
with highly reactive functional groups (epoxides,
quinones, etc.) that may react with DNA or proteins
should generally be avoided [23]. Caution should also
be extended to compounds with functional groups that
have the potential to be converted into reactive species
by metabolism (e.g. nitro compounds). There are clearly
exceptions, however, since several successful drugs do
contain those functionalities.
The collections used for screening would ideally contain
only compounds that meet the criteria for good pharma-
cokinetic properties and an absence of overt toxicity
potential. Nevertheless, there are examples of successful
drugs that do violate the Lipinski Rule of 5. On the con-
trary, there can be no doubt that the overall success of a
drug discovery project is increased if the compound col-
lections used for HTS are heavily biased towards drug-
like properties.
Examples of screening successes
The following examples are selected to illustrate how HTS
is already impacting in a major way on new cancer drug
development. These examples are illustrative and not
exhaustive. Some of the agents described already have
proven clinical utility, while others are in early or late-stage
clinical development. In addition, a number of compounds
with less than ideal selectivity or pharmacological proper-
ties have nevertheless proved to be valuable laboratory
tools to further probe the function of selected signalling
pathways. Also, it is highly probable that a number of as
yet undisclosed compounds have been discovered in drug
discovery programmes that include HTS.
HTS has played a major role in the discovery and develop-
ment of several protein kinase inhibitors. These include the
4-anilinoquinazoline ZD1839 (Iressa; Fig. 2), an ATP com-
petitive inhibitor of the epidermal growth factor receptor
tyrosine kinase that blocks downstream signalling path-
ways involved with the proliferation and survival of cancer
cells. The drug shows activity in non-small-cell lung cancer,
head and neck cancer, and hormone-resistant prostate
cancer, and is currently being evaluated in randomised
phase III clinical trials [24]. A role in the treatment of breast
cancer, including oestrogen-independent disease, might
be anticipated. Iressa will probably be used extensively in
combination with cytotoxic agents in various cancers.
Optimisation of the properties of kinase inhibitors identified
by HTS has led to perhaps the currently best-known
example of a mechanism-based, genome-targeted cancer
drug. Gleevec (STI-571; Fig. 2) inhibits the constitutive
kinase activity of the Bcr-Abl oncoprotein that is responsi-
ble for driving malignancy in chronic myeloid leukaemia
[25]. Outstanding activity has been seen, leading to rapid
regulatory approval in that disease. Gleevec also shows
remarkable activity in a type of sarcoma, known as gastro-
intestinal stromal tumours, that are driven by c-Kit mutations.
Gleevec was found to inhibit the c-Kit receptor tyrosine
kinase with similar potency to its effects on Bcr-Abl. Effects
on c-Kit may also lead to activity in other tumours, including
small-cell lung cancer. Exploitation of the less potent inhibi-
tion of the platelet-derived growth factor receptor tyrosine
kinase could lead to an even broader spectrum of activity.
Additional examples of kinase inhibitors identified through
screening include the vascular endothelial growth factor
receptor (Flk-1/KDR) inhibitor SU5416 [26] (Fig. 2), and a
number of other drugs acting on this target are now
emerging.
Moving on to targets further down the signalling pathways
from receptor kinases, a number of drugs that are based
on leads emerging from HTS are now entering clinical
trials [27]. Inhibitors of protein farnesyl transferases, such
as R115777 (Fig. 2) and SCH66336, are showing152
promise, despite the fact that these may exert their effects
by mechanisms that involve farnesylation but do not
directly involve Ras. Activity has been seen with R115777
in breast cancer (see final section).
Inhibitors of c-Raf-1 and mitogen-activated protein kinase
kinase (MEK) have also been identified by screening, and
have subsequently been optimised into drugs that are now
in clinical trials [27]. For example, BAY 43-9006 (Fig. 2), a
specific inhibitor of the kinase activity of Raf-1, was selected
as a clinical candidate from a compound series identified in
a biochemical screen of Raf-1 kinase activity [28]. Using
another approach, a biochemical cascade assay [29] identi-
fied the MEK inhibitor PD-098059 that eventually led to the
synthesis of the drug known as PD184352 or CI-1040
(Fig. 2) [30]. This drug showed impressive preclinical activ-
ity and is currently in clinical trials. Another MEK inhibitor,
U0126, was identified in a cell-based reporter screen for
inhibitors of AP-1 transactivation [31]. Although unsuitable
for clinical development, this compound has proved to be
extremely useful for probing the cellular consequences of
Ras pathway inhibition.
Considerable effort has been expended on the search to
find compounds that modulate the activity of the tumour
suppressor gene product p53. Not all validated targets for
which screens can be developed have provided progress-
ible leads, and the Holy Grail of ‘mutant p53 resurrection’
has proved fairly intractable. Recent studies have shown,
however, that the function of mutant p53 can be restored
by exposing cells to small molecule compounds identified
in a novel screen that used antibodies to measure confor-
mational changes to the p53 protein [32]. A range of other
strategies to exploit the p53 pathway are also being
pursued; for example, screening for inhibitors of the inter-
action between p53 and HDM2 is a promising approach
[33]. Taking a somewhat different tack, inhibitors of wild-
type p53-dependent gene transcription and apoptosis
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Figure 2
The chemical structures of some of the molecularly targeted compounds that have progressed to clinical trial. Physicochemical characteristics
relating to the Lipinski Rule of 5 (see text) are also shown. MW, molecular weight.153
were identified using a reporter gene under the control of
a p53-responsive promoter [34]. If confirmed, such agents
could be used to protect normal tissues from the side
effects of cytotoxic chemotherapy.
Genome-based cell-cycle modulators are of considerable
therapeutic interest, and inhibitors of cyclin-dependent
kinases such as flavopiridol and R-roscovitine (CYC202;
Fig. 2) are in clinical development. These could compensate
for the loss of polypeptide inhibitors of cyclin-dependent
kinases that is commonly seen in many tumours, including
breast cancer, and could also induce tumour-selective
apoptosis due to deregulated E2F [35,36]. Efforts have
been made to identify drugs that would block the G2 cell-
cycle checkpoint (e.g. inhibitors of Chk1 or Wee1) [37].
The therapeutic rationale for these inhibitors is that in a
p53 non-functional tumour cell, radiosensitisation or
chemosensitisation would occur as both the G1 and G2
checkpoints would be abrogated. In normal cells, damage
due to chemotherapeutic agents or radiation would be min-
imised due to the presence of a robust p53 checkpoint.
Novel mitotic inhibitors have been identified in several
screens. For example, a cell-based ELISA using an antibody
to a mitotic marker, phosphorylated nucleolin, was used to
identify several novel inhibitors of mitosis [38]. Deconvolu-
tion of the hits identified a compound, monastrol, that was
shown to inhibit the motility of the kinesin Eg5 but had no
direct effect on microtubules.
As a final example, a three-step invasion screen [39] was
used to interrogate a natural product library. This lead to the
identification of compounds that inhibit invasion and angio-
genesis without being cytotoxic or affecting cellular adhesion.
Concluding remarks and applications to
breast cancer
We face the exciting prospect that every genetic lesion
involved with the generation and maintenance of the
malignant phenotype will soon be defined in all malignan-
cies including breast cancer. This leads to the challenge
of finding potent and selective drugs that can be used to
reverse or control each of these molecular pathogenic
events. The place of HTS in this process is ensured at
least for the foreseeable future. For breast cancer, there
are a number of drug development targets (or target path-
ways), in addition to those already mentioned in the previ-
ous section, that may have particular relevance. These
include the phosphoinositide 3′-kinase signalling pathway,
various cell-cycle regulation targets (in particular, the inhi-
bition of cyclin D and cyclin E [40], the mitotic kinase
Aurora 2 [41]), the molecular chaperone Hsp90 [42,43],
the HIF-1α signalling pathway in tumour progression and
angiogenesis [44,45], and enzymes involved with chro-
matin modification (e.g. histone acetyltransferases and
histone deacetylases) [5,46,47].
The treatment of breast cancer by a molecularly targeted,
cancer genome-based strategy has already been success-
fully demonstrated with the use of Herceptin, a humanised
antibody to the ErbB2 receptor [48]. Clinical benefit using
this agent is greater in the 20–30% of breast cancer
patients that overexpress the receptor on the surface of
their tumour cells. The farnesyltransferase inhibitor
R115777 (see earlier) is an example of an agent, devel-
oped from an HTS screening lead, that has shown activity
in human breast cancer xenografts [49] and in patients
with advanced breast cancer [50,51]. The ongoing dis-
section of the genetics and genomics of breast cancer
should bring forward a range of additional new targets for
HTS and rational drug design.
Molecular mechanism-based drug discovery is well placed
to provide the small-molecule drugs that, either alone or in
combination with cytotoxic drugs, are required to further
improve response rates and survival in individual patients
with breast cancer and other malignancies. Of course, it
can take a considerable length of time to fully define the
role of any new mechanism-based agent in cancer treat-
ment, as shown by the recent Arimidex, Tamoxifen, Alone
or in Combination Trial demonstrating the value of the aro-
matase inhibitor Arimidex (anastrazole) in the treatment of
postmenopausal breast cancer [52].
There have been prominent criticisms of the ability of new
technologies such as genomics, HTS and combinatorial
chemistry to deliver the required stream of blockbusters to
the pharmaceutical industry across all therapeutic areas
[53]. It will be clear from the examples listed in this brief
review, however, that these technologies, and most cer-
tainly HTS, have already played an important role in bring-
ing innovative new agents to the cancer clinic for patient
benefit.
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